---
title: "ASCLETIS-B granted a total of 650,000 stock options"
description: "According to the announcement from ASCLETIS-B, the company granted stock options to 10 participants (grantees) on September 30, 2025, under the stock option plan adopted by the company on February 3, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259561720.md"
published_at: "2025-09-30T14:09:03.000Z"
---

# ASCLETIS-B granted a total of 650,000 stock options

> According to the announcement from ASCLETIS-B, the company granted stock options to 10 participants (grantees) on September 30, 2025, under the stock option plan adopted by the company on February 3, 2025 (2025 Stock Option Plan), to subscribe for a total of 650,000 shares of the company's common stock with a par value of USD 0.0001 per share

According to the announcement from Ascletis Pharma-B (01672), the company granted stock options to 10 participants (grantees) under the stock option plan adopted on February 3, 2025, to subscribe for a total of 650,000 shares of the company's common stock with a par value of USD 0.0001 per share on September 30, 2025

### Related Stocks

- [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GIC Private Limited 以每股 12.18 港元的價格，投資了歌禮制藥-B，共計 64,128,000 股 | 新加坡政府投資公司（GIC Private Limited）通過以每股 12.18 港元的價格購買 64,128,000 股，獲得了歌禮制藥的股份，總金額約為 7.8108 億港元（1 億美金）。此次投資使 GIC 在該公司中持有 6.42 | [Link](https://longbridge.com/en/news/275105288.md) |
| 歌禮制藥通過私人股份配售籌集了 8.44 億港元 | 歌禮制藥公司成功通過私募發行 69,256,000 股新股，籌集了 844 百萬港元，每股價格為 12.18 港元。這些股份向至少六家機構投資者提供，並根據美國證券法的 S 條款和 144A 規則在美國以外進行配售，未在美國進行任何公開發行 | [Link](https://longbridge.com/en/news/275434090.md) |
| GIC 向歌禮制藥（1672.HK）投資 1 億美元：錨定中國核心創新藥資產的長期資本 | GIC 通過以每股平均 12.18 港元的價格收購 64,128,000 股，向 Ascletis Pharma（1672.HK）投資了約 1 億美元。這項投資標誌着 GIC 進入 Ascletis Pharma 的股東基礎，突顯出對中國創 | [Link](https://longbridge.com/en/news/275106794.md) |
| 歌禮制藥通過配售股份籌集 8.35 億港元，以資助肥胖藥物的試驗 | 歌禮制藥計劃通過以每股 12.18 港元的價格配售 69,256,000 股新股，籌集約 8.35 億港元，約佔其現有股本的 6.98%。這些資金將主要用於支持其肥胖藥物 ASC30 的全球第三階段臨牀試驗，其餘部分用於營運資金。此次配售需 | [Link](https://longbridge.com/en/news/274573426.md) |
| 歌禮制藥宣佈進行新股的私人配售 | 歌禮制藥公司宣佈在一般授權下進行新股的私募發行。這些股份將僅向符合條件的機構投資者提供，符合美國證券法第 144A 條款的註冊要求豁免，並根據 S 條款在美國以外出售。美國不計劃進行公開發行 | [Link](https://longbridge.com/en/news/274571020.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.